Dupilumab-associated sezary syndrome

Dupilumab-associated sezary syndrome

Dupilumab is a monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13), approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD). While recent reports have described cases of new-onset mycosis fungoides (MF) following treatment with dupilumab for...

Full description

Bibliographic Details
Main Authors: Austin Hamp, Jamie Hanson, Albert Alhatem, Robert A Schwartz
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2023-01-01
Series:Indian Journal of Dermatology
Subjects:
atopic dermatitis
dupilumab
mycosis fungoides
sézary syndrome
Online Access:http://www.e-ijd.org/article.asp?issn=0019-5154;year=2023;volume=68;issue=4;spage=459;epage=462;aulast=Hamp

Internet

http://www.e-ijd.org/article.asp?issn=0019-5154;year=2023;volume=68;issue=4;spage=459;epage=462;aulast=Hamp

Similar Items